Catalent (CTLT) Hisse Fiyat
Catalent Fiyat
Catalent, son 15 yılda gelirini yıllık %7,9 artırarak 4,38 Md USD seviyesine taşıdı. Hisse başına kâr, son 8 yılda yıllık %46,7 büyüdü. Catalent için net marj, %-23,8 ile birkaç yıl önceki %5,6 seviyesine göre geriledi. Catalent için 12 aylık konsensüs fiyat hedefi 64,77 USD; bu, hissenin bugünkü fiyatının yaklaşık %2,0 üzerinde bir seviyeye denk geliyor. 14 analistten 0 tanesi hisse için alım öneriyor — genel konsensüs: Tut.
Catalent hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Catalent iş modeli ve hisse analizi
Catalent hakkında sık sorulan sorular
Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.
Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.
Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.
Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.
Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.
Analistler şu anda Catalent hissesi için ortalama 64,77 USD hedef fiyat belirliyor (medyan: 64,77 USD); bu, son fiyata göre +2,0 % anlamına gelir. Konsensüs 14 analist notuna dayanır.
14 analist şu anda Catalent hissesini değerlendiriyor: 0 al, 11 tut, 3 sat öneriyor. 2026 için analistler Catalent şirketinin 5,00 Md USD gelir ve 1,75 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Catalent hissesi 57,55 EUR (63,48 USD) seviyesindedir.
Catalent hissesi (CTLT) 4 borsada işlem görür, bunlar arasında: NYSE (CTLT), SIX (Zürich) (0C8.SW), Frankfurt (0C8.F), München (0C8.MU).
Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.
beklenen'nin Catalent hasılatı 5,00 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Catalent karı 318,65 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Catalent'nin Fiyat/Kazanç (F/K) oranı şu anda 36,26'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Catalent hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Catalent'nin Fiyat/Satış (F/S) oranı şu anda 2,31'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Catalent hisse senedinin değerleme metriği olarak hizmet eder.
Catalent'nin Eulerpool Kalite Puanı 2/10'dur.
Catalent'nin ISIN'i US1488061029'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Catalent'nin WKN'i A112H2'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Catalent'nin ticker'ı CTLT'dir. Ticker sembolü, Catalent hisseleri borsada işlem görmek için kullanılır.
Catalent Hissesi
Catalent Emsaller Grubu
Catalent Ticker
Catalent FIGI
Catalent'nin tüm temel göstergeleri ve derinlemesine analizi
Catalent hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Catalent şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: